{"id":990574,"date":"2026-08-05T20:08:51","date_gmt":"2026-08-06T00:08:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-biologics-reports-second-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-08-05T20:08:51","modified_gmt":"2026-08-06T00:08:51","slug":"adma-biologics-reports-second-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-biologics-reports-second-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n 2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year<\/em>\n <\/p>\n

\n 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year<\/em>\n <\/p>\n

\n BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue<\/em>\n <\/p>\n

\n 2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year<\/em>\n <\/p>\n

\n 2Q 2026 Adjusted Net Income<\/em>
\n
\n (<\/em>
\n <\/sup>
\n
\n 1)<\/em>
\n <\/sup>
\n of $39.0 Million, Increasing 8% Year-over-Year<\/em>\n <\/p>\n

\n 2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year<\/em>\n <\/p>\n

\n 2Q 2026 Adjusted EBITDA<\/em>
\n
\n (<\/em>
\n <\/sup>
\n
\n 2)<\/em>
\n <\/sup>
\n of $61.8 Million, Increasing 22% Year-over-Year<\/em>\n <\/p>\n

\n Strong Balance Sheet and Financial Flexibility Support Continued Execution<\/em>\n <\/p>\n

\n ACAAI Abstract Submitted Highlighting Significant Real-World Health Outcomes and Healthcare Resource Utilization Improvements in PI Patients Treated with ASCENIV<\/em>\n <\/p>\n

\n Accelerating ASCENIV Demand and Expanding Real-World Evidence Reinforce ADMA\u2019s Robust Growth Opportunity<\/em>\n <\/p>\n

\n Reiterates FY2026 Financial Guidance<\/em>\n <\/p>\n

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 05, 2026 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (\u201cADMA\u201d or the \u201cCompany\u201d), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its second quarter 2026 financial results and provided a business update.<\/p>\n

\u201cOur second quarter results reflect strong execution across the business and demonstrate the power of ASCENIV\u2019s growth trajectory,\u201d said Adam Grossman, President and Chief Executive Officer of ADMA. \u201cASCENIV continued to outperform, supported by increasing physician adoption, broader prescriber engagement, new patient starts and higher patient utilization. Growth in ASCENIV utilization accelerated in the quarter, with June delivering the strongest sequential month-over-month utilization growth since the first half of 2024. BIVIGAM demand continued to stabilize during the quarter, resulting in sequential improvement in utilization and revenue. Together, these trends reinforce our confidence in sustained growth throughout the balance of 2026.”<\/p>\n

Mr. Grossman continued, \u201cDuring the first half of 2026, ADMA further enhanced its robust real-world health outcomes and healthcare resource utilization data, which we believe further differentiates ASCENIV in later-line, refractory and medically complex primary immunodeficiency patients. We generated data comprising 127 real-world ASCENIV-treated patients, the majority of whom had previously received other immune globulin therapies and switched to ASCENIV. The study\u2019s findings demonstrated that patients experienced statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, oral antibiotic use and corticosteroid use following ASCENIV administration, and the findings have been submitted as an abstract to the November 2026 American College of Allergy, Asthma & Immunology (\u201cACAAI\u201d) Annual Scientific Meeting. Supported by this expanding real-world evidence base, we believe these datasets will further strengthen ASCENIV\u2019s already robust patient access and commercial payer coverage. We believe ASCENIV remains early in its penetration of this underserved market, supporting our confidence in meeting or exceeding guidance ranges for 2026 and unwavering optimism in the product\u2019s peak revenue potential.\u201d<\/p>\n

\n Reiterated FY2026 Financial Guidance<\/strong>\n <\/p>\n